Uniplan Investment Counsel, Inc. Bristol Myers Squibb CO Transaction History

Uniplan Investment Counsel, Inc.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$53.63 - $62.52 $2.98 Million - $3.48 Million	-55,619 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$59.17 - $69.31 $9,940 - $11,644	-168 Reduced 0.3%	55,619 $3.29 Million
Q2 2021 Aug 13, 2021	SELL	$61.91 - $67.42 $199,845 - $217,631	-3,228 Reduced 5.47%	55,787 $3.73 Million
Q1 2021 May 14, 2021	SELL	$59.34 - $66.74 $229,111 - $257,683	-3,861 Reduced 6.14%	59,015 $3.73 Million
Q4 2020 Feb 12, 2021	SELL	$57.74 - $65.43 $314,105 - $355,939	-5,440 Reduced 7.96%	62,876 $3.9 Million
Q3 2020 Nov 13, 2020	SELL	$57.43 - $63.64 $261,076 - $289,307	-4,546 Reduced 6.24%	68,316 $4.12 Million
Q2 2020 Aug 14, 2020	SELL	$54.82 - $64.09 $636,898 - $744,597	-11,618 Reduced 13.75%	72,862 $4.28 Million
Q1 2020 May 15, 2020	BUY	$46.4 - $67.43 $284,803 - $413,885	6,138 Added 7.83%	84,480 $4.71 Million
Q4 2019 Feb 14, 2020	BUY	$49.21 - $64.19 $3.86 Million - $5.03 Million	78,342 New	78,342 $5.03 Million

2,533

1.47B

31.6M

35M

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $125B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

Get notified when there are updates to the investment portfolio of Uniplan Investment Counsel, Inc., based on Form 13F filings with the SEC.

Stay updated on Uniplan Investment Counsel, Inc. with notifications on news.